subjects to whom any of the following applies will be excluded from the study: pregnant or breastfeeding females. patients unable to receive s-1226; particularly if receiving oxygen therapy by face mask or non invasive ventilatory support patient requires extracorporeal membrane oxygenation (ecmo) and/or invasive mechanical ventilation presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (anc) less than 0.5 x 109 / l. aspartate aminotransferase (ast)/alanine aminotransferase (alt) greater than 5 x upper limit of normal (uln). platelets less than 50 x109 / l. in the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment. subject, who in the opinion of the investigator, is unsuitable to participate

subjects to whom any of the following applies will be excluded from the study: pregnant or breastfeeding females. patients unable to receive s-1226; particularly if receiving oxygen therapy by face mask or non invasive ventilatory support patient requires extracorporeal membrane oxygenation (ecmo) and/or invasive mechanical ventilation presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (anc) less than 0.5 x 109 / l. aspartate aminotransferase (ast)/alanine aminotransferase (alt) greater than 5 x upper limit of normal (uln). platelets less than 50 x109 / l. in the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment. subject, who in the opinion of the investigator, is unsuitable to participate

- subjects to whom any of the following applies will be excluded from the study: 1. pregnant or breastfeeding females. 2. patients unable to receive s-1226; particularly if receiving oxygen therapy by face mask or non invasive ventilatory support 3. patient requires extracorporeal membrane oxygenation (ecmo) and/or invasive mechanical ventilation 4. presence of any of the following abnormal laboratory values at screening: 1. absolute neutrophil count (anc) less than 0.5 x 109 / l. 2. aspartate aminotransferase (ast)/alanine aminotransferase (alt) greater than 5 x upper limit of normal (uln). 3. platelets less than 50 x109 / l. 5. in the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment. 6. subject, who in the opinion of the investigator, is unsuitable to participate

- subjects to whom any of the following applies will be excluded from the study: 1. pregnant or breastfeeding females. 2. patients unable to receive s-1226; particularly if receiving oxygen therapy by face mask or non invasive ventilatory support 3. patient requires extracorporeal membrane oxygenation (ecmo) and/or invasive mechanical ventilation 4. presence of any of the following abnormal laboratory values at screening: 1. absolute neutrophil count (anc) less than 0.5 x 109 / l. 2. aspartate aminotransferase (ast)/alanine aminotransferase (alt) greater than 5 x upper limit of normal (uln). 3. platelets less than 50 x109 / l. 5. in the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment. 6. subject, who in the opinion of the investigator, is unsuitable to participate